



Correction to: Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Heart Failure Events in Patients with Type 2 Diabetes Mellitus: A Cost Per Outcome Analysis

Ronen Arbel¹ · Enis Aboalhasan¹ · Ariel Hammerman² · Joseph Azuri^{3,4}

Published online: 6 June 2020
© Springer Nature Switzerland AG 2020

Correction to: Clinical Drug Investigation
<https://doi.org/10.1007/s40261-020-00929-z>

The original version of this article unfortunately contained a mistake. The correct information is given below.

Abstract—Results, 1st sentence, which previously read:

We figured empagliflozin's CNT to be \$664,464 (95% CI \$499,872–\$1,097,280), \$1,535,387 (95% CI \$886,074–\$3,210,501) for canagliflozin, and \$2,693,145 (95% CI \$1,639,563–\$11,092,206) for dapagliflozin.

Should read:

We figured empagliflozin's CNT to be \$664,464 (95% CI \$499,872–\$1,097,280), \$1,353,387 (95% CI \$886,074–\$3,210,501) for canagliflozin, and \$2,693,145 (95% CI \$1,639,563–\$11,092,206) for dapagliflozin.

The original article can be found online at <https://doi.org/10.1007/s40261-020-00929-z>.

✉ Ronen Arbel
ronen.arbel@gmail.com

¹ Maximizing Health Outcomes Research Lab, Department of Technology Marketing, Sapir College, D.N. Hof Ashkelon, 79165 Sderot, Israel

² Department of Pharmaceutical Technology Assessment, Clalit Health Services Headquarters, Tel-Aviv, Israel

³ Diabetes Clinic, Central District, Maccabi Healthcare Services, Tel Aviv, Israel

⁴ Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel